Xencor Inc (XNCR) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
the bull case· 3
22
disclosed supplier and customer ties in SEC filings across partnerships
sec filingsedgar+1.97%
change in shares held by the largest reporting managers over the latest quarter
13fJun 30 '26206
managers reporting a position in filings across institutional investors
13fJun 30 '26the bear case· 4
0.29%
State Street SPDR S P Biotech ETF assets represent the largest fund weight
n-portJun 30 '263 of 24
largest reporting managers cut their stake in the latest quarter
13fJun 30 '264
funds on file reporting a position in the company
n-portas of Jun 30 '2617
managers whose positions together make up most of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 4 '26 report. Not a forecast, not advice.
Of the 6 companies Xencor Inc moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
XNCR (Xencor Inc) has 12 disclosed suppliers and 10 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
tall tick = annual report · 1 on record
207 managers report a position worth $1.4B between them, and 17 of them hold 80% of it.
Xencor Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 24.87 at 10:15 am ET, low 24.22 at 4:00 am ET.